Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117
Heidelberg Pharma AG today announced that its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta; NASDAQ: MGTA) has dosed the first patient with the development candidate MGTA-117 in a Phase I/II study. The achievement of this milestone triggered a milestone payment to Heidelberg Pharma.